A prospective, single-arm, nonrandomised study to evaluate the efficacy and tolerability of nitinol self-expanding biolimus A9-eluting stents in patients with de novo coronary bifurcation lesions.

Trial Profile

A prospective, single-arm, nonrandomised study to evaluate the efficacy and tolerability of nitinol self-expanding biolimus A9-eluting stents in patients with de novo coronary bifurcation lesions.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Nov 2011

At a glance

  • Drugs Umirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms Axxess Plus
  • Most Recent Events

    • 08 Nov 2011 Status changed from active, no longer recruiting to completed, according to a Biosensors International Group media release.
    • 08 Nov 2011 Final results were presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, according to a Biosensors International Group media release. Results were also reported in the media release.
    • 11 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top